[go: up one dir, main page]

MA45244A - Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 - Google Patents

Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1

Info

Publication number
MA45244A
MA45244A MA045244A MA45244A MA45244A MA 45244 A MA45244 A MA 45244A MA 045244 A MA045244 A MA 045244A MA 45244 A MA45244 A MA 45244A MA 45244 A MA45244 A MA 45244A
Authority
MA
Morocco
Prior art keywords
substituted pyridines
pyridines used
dnmt1 inhibitors
dnmt1
inhibitors
Prior art date
Application number
MA045244A
Other languages
English (en)
Inventor
Nicholas David Adams
Andrew B Benowitz
Roger J Butlin
Karen Anderson Evans
David T Fosbenner
Kristin M Goldberg
Allan M Jordan
Christopher S Kershaw
Bryan Wayne King
Mei Li
Juan Ignacio Luengo
William Henry Miller
Ali Raoof
Alexander Joseph Reif
Stuart Paul Romeril
Benede Maria Lourdes Rueda
Stanley J Schmidt
Bohdan Waszkowycz
Original Assignee
Cancer Research Tech Ltd
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Glaxosmithkline Ip Dev Ltd filed Critical Cancer Research Tech Ltd
Publication of MA45244A publication Critical patent/MA45244A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA045244A 2016-06-13 2017-06-13 Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 MA45244A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349227P 2016-06-13 2016-06-13
US201662393256P 2016-09-12 2016-09-12
US201662412343P 2016-10-25 2016-10-25

Publications (1)

Publication Number Publication Date
MA45244A true MA45244A (fr) 2019-04-17

Family

ID=59239935

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045244A MA45244A (fr) 2016-06-13 2017-06-13 Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1

Country Status (21)

Country Link
US (1) US10975056B2 (fr)
EP (1) EP3468953B1 (fr)
JP (1) JP7051829B2 (fr)
KR (1) KR20190017030A (fr)
CN (1) CN109563043B (fr)
AU (1) AU2017283790B2 (fr)
BR (1) BR112018075992A2 (fr)
CA (2) CA3026226A1 (fr)
CL (1) CL2018003577A1 (fr)
CO (1) CO2018013717A2 (fr)
CR (1) CR20180580A (fr)
DO (1) DOP2018000273A (fr)
ES (1) ES2993451T3 (fr)
IL (1) IL263163B (fr)
JO (1) JOP20180120A1 (fr)
MA (1) MA45244A (fr)
MX (1) MX2018015483A (fr)
PE (1) PE20190971A1 (fr)
PH (1) PH12018502633B1 (fr)
SG (1) SG11201809559UA (fr)
WO (2) WO2017216726A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2018000023A1 (en) 2015-08-13 2019-07-08 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists.
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CA2968836A1 (fr) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Composes modulant fxr (nr1h4)
SG11201810600WA (en) 2016-06-13 2018-12-28 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
SG10202008647TA (en) 2016-10-04 2020-10-29 Merck Sharp & Dohme BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
PL4122464T3 (pl) 2017-03-28 2024-09-16 Gilead Sciences, Inc. Kombinacje terapeutyczne do leczenia chorób wątroby
WO2018208667A1 (fr) 2017-05-12 2018-11-15 Merck Sharp & Dohme Corp. Composés dinucléotidiques cycliques en tant qu'agonistes sting
EP3661498A4 (fr) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. Agonistes benzo[b]thiophène de sting pour le traitement du cancer
JP2020529421A (ja) 2017-08-04 2020-10-08 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
WO2019072143A1 (fr) * 2017-10-11 2019-04-18 上海迪诺医药科技有限公司 Dérivé de 4-aminopyridine, composition pharmaceutique contenant celui-ci, procédé de préparation associé et utilisation correspondante
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CA3095646A1 (fr) 2018-04-03 2019-10-10 Merck Sharp & Dohme Corp. Benzothiophenes et composes associes utilises en tant qu'agonistes de sting
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
HUE065889T2 (hu) 2019-01-15 2024-06-28 Gilead Sciences Inc Izoxazol vegyület mint FXR agonista és az azt tartalmazó gyógyszerészeti készítmények
CA3233305A1 (fr) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Formes solides d'agonistes de fxr
CN111662283B (zh) * 2019-03-07 2021-11-16 湖南化工研究院有限公司 咪唑并吡啶类化合物及其中间体、制备方法与应用
US20240002396A1 (en) * 2020-10-07 2024-01-04 University Of Florida Research Foundation, Incorporated Macrocyclic compounds and methods of treatment
KR20230154230A (ko) * 2021-03-02 2023-11-07 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 Dnmt1 억제제로서의 치환된 피리딘
CN113502265B (zh) * 2021-05-25 2024-05-28 昭泰英基生物医药（香港）有限公司 将t细胞重编程为类nk细胞的诱导剂及其应用
CN113278021B (zh) * 2021-05-29 2022-09-23 天津全和诚科技有限责任公司 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
CN114230459A (zh) * 2021-12-10 2022-03-25 武汉九州钰民医药科技有限公司 一种化合物的制备方法及分析检测方法
WO2023192629A1 (fr) * 2022-04-01 2023-10-05 Herophilus, Inc. Induction de l'expression de mecp2 par des inhibiteurs de l'adn méthyl transférase
WO2024156288A1 (fr) * 2023-01-29 2024-08-02 Shanghai Kygent Pharmaceutical Co., Ltd Inhibiteurs de dnmt1, compositions pharmaceutiques et applications thérapeutiques

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2030875C (fr) 1990-11-26 2002-07-02 Alan R.P. Paterson Methodes et sondes pour le depistage de la nucleoside et methode de fabrication de ces sondes
CA2075154A1 (fr) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Aldehydes peptidiques utilises comme agents antithrombotiques
AU6536494A (en) 1993-03-26 1994-10-24 Shell Internationale Research Maatschappij B.V. Herbicidal 1-heteroaryl pyrazolidin-3,5-diones
CN1209060A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
TR199801254T2 (xx) 1995-12-29 1998-10-21 Smithkline Beecham Corporation Vitronektin resept�r� antagonistleri.
DE19947154A1 (de) * 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
EP1242366A1 (fr) 1999-12-15 2002-09-25 Axys Pharmaceuticals, Inc. Salicylamides utiles en tant qu'inhibiteurs des serines proteases
US6794506B2 (en) 2000-07-21 2004-09-21 Elan Pharmaceuticals, Inc. 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4
US20030166554A1 (en) 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
DE10110754A1 (de) 2001-03-07 2002-09-19 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
DE10134481A1 (de) * 2001-07-16 2003-01-30 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
DE10238113A1 (de) * 2001-12-11 2003-06-18 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung
TW200406370A (en) 2002-06-28 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives
TW200406152A (en) 2002-08-30 2004-05-01 Syngenta Participations Ag 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties
US6930117B2 (en) 2002-11-09 2005-08-16 The Procter & Gamble Company N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones
TW200410632A (en) 2002-12-11 2004-07-01 Syngenta Participations Ag Dihalo-allyloxy-phenol derivatives having pesticidal activity
SE0203712D0 (sv) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
JP4895806B2 (ja) 2003-04-09 2012-03-14 エクセリクシス， インク． Ｔｉｅ−２モジュレータと使用方法
EP2281823A3 (fr) 2003-05-20 2011-09-07 Ajinomoto Co., Inc. Derivées de la piperidine anti-inflammatoires et analgésiques
US7692017B2 (en) 2003-09-23 2010-04-06 Merck Sharp & Dohme Corp. Quinoline potassium channel inhibitors
AU2011253934C1 (en) 2004-06-17 2013-08-22 Cytokinetics, Inc. Substituted urea derivatives for treating cardiac diseases
US7776869B2 (en) 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
EP1655296A1 (fr) 2004-10-25 2006-05-10 Graffinity Pharmaceuticals AG Inhibiteurs de la thrombine
EP1844062A2 (fr) 2005-01-21 2007-10-17 Methylgene, Inc. Inhibiteurs d'adn-methyltransferase
GB0517740D0 (en) 2005-08-31 2005-10-12 Novartis Ag Organic compounds
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
ATE528292T1 (de) 2006-06-20 2011-10-15 Ishihara Sangyo Kaisha Schädlingsbekämpfungsmittel mit neuem pyridyl- methanamin-derivat oder salz daraus
US20080132525A1 (en) 2006-12-04 2008-06-05 Methylgene Inc. Inhibitors of DNA Methyltransferase
CN101652365A (zh) 2007-02-01 2010-02-17 阿斯利康(瑞典)有限公司 作为hsp90抑制剂的5,6,7,8-四氢蝶啶衍生物
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009034433A2 (fr) 2007-09-10 2009-03-19 Glenmark Pharmaceuticals, S.A. Dérivés de 3-azabicyclo [3.1.0] hexane utilisés comme ligands des récepteurs vanilloïdes
JP5580201B2 (ja) 2007-10-08 2014-08-27 アドビヌス・セラピューティクス・プライベート・リミテッド グルコキナーゼアクチベータとしてのアセトアミド誘導体、その製法及び医薬応用
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
TW201028381A (en) * 2008-07-14 2010-08-01 Shionogi & Co Pyridine derivative having ttk inhibition activity
TW201011017A (en) 2008-08-19 2010-03-16 Astrazeneca Ab Chemical compounds 495-1
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
WO2010088518A2 (fr) 2009-01-31 2010-08-05 Kalypsys, Inc. Modulateurs hétérocycliques du gpr119 pour le traitement de maladies
KR101146010B1 (ko) * 2009-09-10 2012-05-16 서울대학교산학협력단 ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물
CN102686584A (zh) 2009-11-13 2012-09-19 盐野义制药株式会社 具有氨基连接基的氨基噻嗪或氨基噁嗪衍生物
JP5793505B2 (ja) 2009-12-23 2015-10-14 ジャスコ ファーマシューティカルズ， エルエルシー アミノピリミジンキナーゼ阻害薬
GEP20156243B (en) 2009-12-23 2015-02-10 Takeda Pharmaceutical Fused heteroaromatic pyrrolidinones as syk inhibitors
EP2338888A1 (fr) 2009-12-24 2011-06-29 Almirall, S.A. Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK
WO2011103289A2 (fr) 2010-02-17 2011-08-25 Jasco Pharmaceuticals, LLC Inhibiteurs imidazole-2, 4-dione de la caséine kinase 1
MX351368B (es) 2010-05-26 2017-10-12 Sunovion Pharmaceuticals Inc Compuestos heteroarilo y metodos para utilizarlos.
WO2012040636A2 (fr) 2010-09-24 2012-03-29 The Broad Institute, Inc. Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
CA2824808A1 (fr) 2011-01-17 2012-07-26 Karyopharm Therapeutics, Inc. Modulateurs du transport nucleaire contenant des olefines et leurs utilisations
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2013019635A1 (fr) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et méthodes
WO2013019621A1 (fr) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Composés et méthodes
JP2014530910A (ja) 2011-10-24 2014-11-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ 新規化合物
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
JP6535430B2 (ja) 2012-09-28 2019-06-26 イグニタ、インク． 非定型プロテインキナーゼｃのアザキナゾリン阻害薬
CA2934486A1 (fr) 2014-01-21 2015-07-30 Wockhardt Limited Derives 7-oxo-1,6-diazabicyclo[3.2.1 ]octane et leur utilisation comme agents antibacteriens
WO2015110999A1 (fr) 2014-01-24 2015-07-30 Piramal Enterprises Limited Inhibiteurs de ezh2 et leurs utilisations

Also Published As

Publication number Publication date
PH12018502633A1 (en) 2019-09-30
WO2017216727A1 (fr) 2017-12-21
CN109563043B (zh) 2022-05-31
DOP2018000273A (es) 2019-03-31
EP3468953A1 (fr) 2019-04-17
SG11201809559UA (en) 2018-12-28
PH12018502633B1 (en) 2023-02-01
CN109563043A (zh) 2019-04-02
IL263163A (en) 2018-12-31
CA3026211A1 (fr) 2017-12-21
AU2017283790B2 (en) 2019-08-29
PE20190971A1 (es) 2019-07-09
WO2017216726A1 (fr) 2017-12-21
CA3026226A1 (fr) 2017-12-21
CR20180580A (es) 2019-07-02
IL263163B (en) 2021-10-31
AU2017283790A1 (en) 2018-11-22
JP7051829B2 (ja) 2022-04-11
JOP20180120A1 (ar) 2019-01-30
BR112018075992A2 (pt) 2019-04-02
EP3468953C0 (fr) 2024-05-22
JP2019517596A (ja) 2019-06-24
KR20190017030A (ko) 2019-02-19
MX2018015483A (es) 2019-03-18
US20190194166A1 (en) 2019-06-27
CL2018003577A1 (es) 2019-04-05
CO2018013717A2 (es) 2019-01-18
EP3468953B1 (fr) 2024-05-22
ES2993451T3 (en) 2024-12-30
US10975056B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA53150A (fr) Composés de benzimidazole en tant qu'inhibiteurs de c-kit
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
DK3497103T3 (da) Pyridopyrimdinon-cdk2/4/6-inhibitorer
MA46981A (fr) Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine
MA47125A (fr) Dérivés de pyrazole en tant qu'inhibiteurs de malt1
MA40774A (fr) Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
MA43862A (fr) Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock
MA51878A (fr) Composés d'aminothiazole en tant qu'inhibiteurs de c-kit
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA42990A (fr) Composés utiles en tant qu'immunomodulateurs
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA42659A (fr) Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp
MA40587A (fr) Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA43169A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
EP3416964A4 (fr) Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
MA52123A (fr) Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac